Trial Profile
A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Alectinib (Primary) ; Cobimetinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 07 Mar 2021 Planned End Date changed from 30 Nov 2022 to 30 Nov 2024.
- 07 Mar 2021 Planned primary completion date changed from 30 Nov 2021 to 30 Nov 2022.
- 19 Aug 2020 Planned End Date changed from 30 Aug 2020 to 30 Nov 2022.